我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
66
4 进行中
药物批准
43
批准总数
监管机构
2
监管机构数
成立时间
1994
进行中（未招募）
3.0%
已完成
50
75.8%
尚未招募
招募中
6
9.1%
终止
5
7.6%
撤回
1
1.5%
CANADA
Health Canada
4
CIMA_AEMPS
Spanish Agency for Medicines and Medical Devices
39
- The Usher Syndrome market is poised for growth with emerging therapies addressing the root cause of the disease, offering alternatives to supportive care. - Ultevursen, an investigational RNA therapy, targets the USH2A gene mutation and is currently in Phase II/III trials, showing promise in restoring functional usherin protein. - Nacuity Pharmaceuticals' NPI-001, a free radical scavenger, is in Phase I/II trials, aiming to reduce oxidative stress and preserve photoreceptor cells in Usher Syndrome patients. - The US has the highest prevalent cases of Usher Syndrome, with approximately 21,000 cases in 2023, highlighting the significant unmet need for effective treatments.
